Use of a new polypeptide to treat MRSA and VISA strains

L'innovation

Context: The emergence of multi-drug resistance in bacteria seems to be one of the most issue in human health. In this context, Staphylococcus aureus infectious are the worst case, because of these abilities to bypass immune system and to resist against classical antibiotic.

Issue: Among these abilities, toxin-antitoxin system or TA has been identified as function to trigger bacteria cell death in stress condition. Some of companies have developed molecules targeting toxin or antitoxin, but their efficiency have been limited by a high hemolytic activity.

Solution: In this context, scientists have found a new system TA (type I), involving sprA1 gene which display an antimicrobial activity on S.aureus and other bacteria (gram positive or negative).

The technology developed by research team uses a PepA1-derivative peptides which have been chemically modified (cyclization) allowing bacteria death while avoiding hemolytic activity. Last result have shown a better efficiency on MRSA strains than Vancomycin (IMC: 2µM)

Ses bénéfices
Natural mechanism
Membrane localization

Ses applications
Human health: Nosocomial disease, Multi-drug resistance : S.aureus (MRSA, VISA), E.coli
Animal health: Mastitis

Stade de développement
IN VIVO - Preuve de concept

Laboratoire de recherche
UMR_S 1230 - BRM

Équipe de recherche
Bacterial regulatory RNAs and medecine

Propriété intellectuelle associée
EP : EP14191238 - filed on the 10-31-2014
WO - CA,EP,JP,US